Tuesday, October 2, 2012

Lotriga (Lovaza) Approved in Japan for treatment of Hyperlipidemia - Peak sales of $300m

Takeda and Pronova announced approval of Lotriga for the treatment of Hyperlipidemia in Japan.  Lotriga is sold under the brand name Lovaza in the US by GSK and garners close to $1billion in annual sales.  The opportunity size in terms of volume for omega 3 in Japan is about 25% of the global sales and is currently dominated by a single agent, which suggests high barriers to entry for OTC players. We estmate peak sales of $300million for Lotriga in Japan.